• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by BGM Group Ltd.

    2/28/25 6:01:01 AM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BGM alert in real time by email
    6-K 1 tm257799d1_6k.htm FORM 6-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of February 2025

      

    BGM Group Ltd

     

    No. 152 Hongliang East 1st Street, No. 1703,

    Tianfu New District, Chengdu, 610200

    People’s Republic of China

    +86-028-64775180

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F x Form 40-F ¨

     

     

     

     

     

     

    Change of Directors

     

    Resignation of Mr. Zhanchang Xin and Appointment of Mr. Chen Xin as the Chairman of the Board

     

    On February 28, 2025, Mr. Zhanchang Xin notified the Company of his resignation as the Chairman of the board of directors of the Company (the “Board”), with effect on and from March 1, 2025. Mr. Zhanchang Xin has advised that his resignation was due to personal reasons and not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company. 

     

    To fill in the vacancy created by the resignation of Mr. Zhanchang Xin, the Board appointed and approved the appointment of Mr. Chen Xin as the Chairman of the Board, with effect on and from March 1, 2025.

     

    Mr. Chen Xin has served as our Chief Executive Officer since May 2024, during which he has led and participated in the merger and acquisition of DuXiaoBao Intelligent Technology (Shenzhen) Co., Ltd. and he currently serves as a member of its management committee (DuXiaoBao project). Since 2021, he successively served as an autonomous driving algorithm engineer at Shenzhen Dajiang Innovation Technology Co., Ltd. and Geely Automobile Research Institute, being responsible for algorithm work related to image processing, multi-sensor target detection, perception fusion and target behavior prediction in autonomous driving. He has managed the implementation of several mass production projects and has extensive practical experience in the fields of artificial intelligence and data analysis. Mr. Chen Xin obtained his bachelor’s degree in physics from Sichuan University in 2016 and his master’s degree in physics from the National University of Singapore in 2021, focusing on the interdisciplinary field of physics and machine learning. His graduate thesis mainly revolves around the image processing of electron microscopy and machine learning algorithms, specializing in the prediction of three-dimensional protein molecular structures based on image processing.

     

    Mr. Chen Xin signed a director offer letter with the Company, which establishes certain terms and conditions governing his services to the Company. The offer letter is qualified in its entirety by reference to the complete text of the offer letter, which is filed hereto as Exhibit 99.1.

     

    Resignation of Mr. Ming Jing and Appointment of Mr. Lin Zhang as an Independent Director of the Board

     

    On February 28, 2025, Mr. Ming Jing notified the Company of his resignation as an independent Director, the Chairman of the Compensation Committee, a member of the Audit Committee and Nominating and Corporate Governance Committee of the Board of the Company, with effect on and from March 1, 2025. Mr. Ming Jing has advised that his resignation was due to personal reasons and not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company. 

     

    To fill in the vacancy created by the resignation of Mr. Ming Jing, the Board appointed Mr. Lin Zhang to serve as an independent Director, the Chairman of the Compensation Committee, a member of the Audit Committee and Nominating and Corporate Governance Committee of the Board of the Company, with effect on and from March 1, 2025.

     

    Mr. Lin Zhang has extensive experience in the structuring, development, and mass-production implementation of AI models. Since August 2023, Mr. Zhang has been serving as the principal algorithm engineer at Geely Automobile Research Institute, where he leads the architectural design, algorithm development, and engineering implementation of deep learning-based intelligent driving planning models in mass-production vehicle projects. From May 2022 to July 2023, Mr. Zhang worked as an algorithm engineer at Shanghai Yunji Zhixing Intelligent Technology Co., Ltd., where he led the development of multimodal trajectory prediction AI models for the Robotaxi project, achieving interaction modeling of multiple agents in complex urban scenarios. Mr. Zhang obtained his Ph.D. in Physics from the National University of Singapore in 2021, focusing on theoretical research of deep learning networks in artificial intelligence during his doctoral studies. He received his bachelor’s degree in physics from Sichuan University in 2016.

     

    Mr. Lin Zhang does not have a family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.

     

     

     

     

    The Board has determined that Mr. Lin Zhang satisfies the applicable independence requirements as an independent Director and a member of the Audit Committee of the Company as stipulated under Nasdaq Listing Rule 5605(a)(2).

     

    Mr. Lin Zhang signed a director offer letter with the Company, which establishes certain terms and conditions governing his services to the Company. The offer letter is qualified in its entirety by reference to the complete text of the offer letter, which is filed hereto as Exhibit 99.2.

     

    EXHIBIT INDEX

     

    Exhibit No.                                                                    Description
    99.1   Director Offer Letter, dated March 1, 2025, by and between Mr. Chen Xin and the Company
    99.2   Director Offer Letter, dated March 1, 2025, by and between Mr. Lin Zhang and the Company

     

     

     

     

       

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Dated: February 28, 2025

     

      BGM Group Ltd
         
      By: /s/ Chen Xin
      Name:  Chen Xin
      Title: Chief Executive Officer

     

     

     

     

     

     

     

    Get the next $BGM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BGM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BGM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BGM To Report First Half 2025 Unaudited Financial Results on July 24, 2025

    CHENGDU, China, July 23, 2025 /PRNewswire/ -- BGM Group (the "Company" or "BGM") (NASDAQ:BGM) today announced that it will release its unaudited financial results for the first half 2025 before the U.S. financial markets open on July 24, 2025 Eastern Daylight Time. About BGM  BGM Group Ltd. has a strategic focus on the technology fields of AI application, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals. In terms of AI application implementation, the group relies on advanced analytics and AI Agent technology, and utilizes the two platforms of Du Xiao Bao and Bao Wang to provide comprehensive and professional AI solutions and intelligent robot services

    7/23/25 6:36:00 AM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    From Virtual Agents to Embodied and Industry-Specific AI: BGM Acquires Xingdao Intelligent and YD Network, Advancing AI on Two Fronts

    CHENGDU, China, May 28, 2025 /PRNewswire/ -- BGM Group Ltd. (the "Company" or BGM)  (NASDAQ:BGM) today announced that it has entered into definitive transaction agreements with the existing shareholders of Xingdao Intelligent Cloud Chain (Shenzhen) Co., Ltd. ("Xingdao Intelligent") and YD Network Technology Company Limited ("YD Network"). Under the terms of the agreements, BGM will acquire 100% of the equity interests of both companies at a combined valuation of RMB800 million. The consideration will be paid through the issuance of 37,123,142 newly issued Class A ordinary shares of BGM at a price of US$3.0 per share. The transactions are expected to close by the end of June 2025, subject to

    5/28/25 4:30:00 PM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BGM Group Announces Strategic Acquisition of HM Management to Expand AI Application Ecosystem

    CHENGDU, China, May 2, 2025 /PRNewswire/ -- BGM Group Ltd. (NASDAQ:BGM) (the "Company" or "BGM") , a leading AI technology company, today announced it has entered into a definitive agreement (the "Agreement") to acquire HM Management Company Limited ("HM Management"), a prominent AI agent production platform, in an all-stock transaction valued at approximately RMB300 million (US$41.7 million). Under the Agreement, BGM will issue 16,663,427 Class A ordinary shares at $2.50 per share to acquire 100% ownership of HM Management and its two wholly-owned subsidiaries: Beijing Shuda Technology Company Limited. ("Shuda Technology") and New Media Star Technology (Shenzhen) Co., Ltd ( "New Media Star

    5/2/25 8:30:00 AM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGM
    SEC Filings

    View All

    SEC Form 6-K filed by BGM Group Ltd.

    6-K - BGM Group Ltd. (0001779578) (Filer)

    7/24/25 7:31:02 AM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by BGM Group Ltd.

    6-K - BGM Group Ltd. (0001779578) (Filer)

    6/26/25 6:04:07 AM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by BGM Group Ltd.

    S-8 - BGM Group Ltd. (0001779578) (Filer)

    6/3/25 4:31:34 PM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGM
    Leadership Updates

    Live Leadership Updates

    View All

    BGM Group Announces Board Reshuffle: New Leadership Embarks on a Transformative Journey Amid Tech Revolution

    CHENGDU, China, Feb. 28, 2025 /PRNewswire/ -- BGM Group Ltd (NASDAQ:BGM) (the "Company" or "BGM") today announced changes to its board of directors, marking the Company's entry into a new phase of technological transformation and sustainable growth. Mr. Zhanchang Xin has tendered his resignation and will step down from his role as Chairman of the Company, effective March 1, 2025. He will be succeeded by Mr. Chen Xin, the current Chief Executive Officer of the Company, who will assume the position of Chairman. As the founder of the Company, Mr. Zhanchang Xin has, over the past six decades, has played a pivotal role in leading the Company through numerous challenges and milestones, including

    2/28/25 8:30:00 AM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BGM Group Establishes "Duxiaobao Management Committee" to Accelerate AI Strategy and Drive Intelligent Transformation in the Insurance Industry

    CHENGDU, China, Feb. 19, 2025 /PRNewswire/ -- BGM Group Ltd. (NASDAQ:BGM) announced the establishment of the "Duxiaobao Management Committee," which will be fully responsible for the management and decision-making of the "Duxiaobao" ecosystem. This move signifies BGM Group's strategic entry into the field of artificial intelligence, aiming to accelerate the transformation of the insurance industry into the smart era through AI technology. The Duxiaobao Management Committee consists of industry leaders such as Xin Chen, Li Yuqing, Ge Peng, Zhao Qi, Ren Yong, Li Jun, Zhou Xin, and Wang Hui. The committee has appointed Li Yuqing as the CEO of Duxiaobao, with Li Jun, Ren Yong, Zhou Xin, and Tan

    2/19/25 7:30:00 AM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGM
    Financials

    Live finance-specific insights

    View All

    From Virtual Agents to Embodied and Industry-Specific AI: BGM Acquires Xingdao Intelligent and YD Network, Advancing AI on Two Fronts

    CHENGDU, China, May 28, 2025 /PRNewswire/ -- BGM Group Ltd. (the "Company" or BGM)  (NASDAQ:BGM) today announced that it has entered into definitive transaction agreements with the existing shareholders of Xingdao Intelligent Cloud Chain (Shenzhen) Co., Ltd. ("Xingdao Intelligent") and YD Network Technology Company Limited ("YD Network"). Under the terms of the agreements, BGM will acquire 100% of the equity interests of both companies at a combined valuation of RMB800 million. The consideration will be paid through the issuance of 37,123,142 newly issued Class A ordinary shares of BGM at a price of US$3.0 per share. The transactions are expected to close by the end of June 2025, subject to

    5/28/25 4:30:00 PM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BGM Group Acquires Wonder Dragon to Accelerate "Healthcare" Strategy

    CHENGDU, China, April 21, 2025 /PRNewswire/ -- BGM Group Ltd. (NASDAQ:BGM) today announced that it has signed a definitive transaction agreement with the existing shareholders of Wonder Dragon Global Limited ("Wonder Dragon"), to acquire 100% of the equity interests of Wonder Dragon by issuing 38,165,290 Class A ordinary shares at a price of $2 per share, for a total transaction valuation of RMB550 million. The transaction is expected to be completed in the second quarter of 2025. Wonder Dragon possesses over 3,000 metric tons of premium Qingzhuan dark tea inventory, comprising 1,670 metric tons of raw materials and 1,350 metric tons of finished products. These premium tea products, known f

    4/21/25 8:30:00 AM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BGM Acquires YX to Strengthen AI Strategy for Its Intelligent Platform

    CHENGDU, China, March 19, 2025 /PRNewswire/ -- BGM Group Ltd. (the "Company" or BGM) (NASDAQ:BGM) today announced that it has signed a definitive agreement with the existing shareholders of YX Management Company Ltd. ("YX"), a smart mobility technology company. Under the agreement, BGM will acquire 100% of the equity interests of YX by issuing 47.5 million class A ordinary shares to its existing shareholders, valuing YX at US$95.0 million. This acquisition is based on the exceptional expertise and experience of the YX team in scalable operations, digital infrastructure development, and technology commercialization. The integration of this team will accelerate the AI-driven strategic upgrade

    3/19/25 8:30:00 AM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by BGM Group Ltd.

    SC 13D - BGM Group Ltd. (0001779578) (Subject)

    12/3/24 6:03:06 AM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by BGM Group Ltd.

    SC 13D/A - BGM Group Ltd. (0001779578) (Subject)

    11/29/24 9:00:27 AM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Qilian International Holding Group Ltd.

    SC 13D - Qilian International Holding Group Ltd (0001779578) (Subject)

    10/16/24 4:19:46 PM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care